Abstract
Objective To investigate the clinical value of human epididymis secretory protein 4 (HE4) in the diagnosis of ovarian cancer. Methods A total of 105 patients with ovarian carcinoma from July 2014 to December 2015 were selected as observation group, and another 90 cases with benign ovarian lesions were selected as control group A and 130 cases of healthy people were selected as control group B, the serum CA125 and HE4 levels of the three groups were determined, and the test result were analysiss. Results The serum level of HE4 in observation group were significantly higher than that in the control group, the difference was significant (P 0.05). Conclusions Serum HE4 is a good marker for ovarian cancer; it can contribute to effective identification of uterine benign and malignant lesions, and have very positive role in the early diagnosis of ovarian cancer, so it is recommended to be further promoted in the clinics to improve the early diagnosis of ovarian cancer. Key words: Ovarian cancer; Human epididymal epithelial secretory protein 4; Pathological diagnosis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
